Kosiborod M, Birkeland KI, Cavender MA, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study. Diabetes Obes Metab. 2018;20:1983--1987. 10.1111/dom.13299 29569378

**Funding information** This work was supported by AstraZeneca.

1. INTRODUCTION {#dom13299-sec-0001}
===============

Despite advances in prevention, cardiovascular disease remains the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Two large randomized controlled trials (RCTs) of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2i; empagliflozin and canagliflozin) have shown significant reductions in major adverse cardiac events, as well as in hospitalizations for heart failure.[1](#dom13299-bib-0001){ref-type="ref"}, [2](#dom13299-bib-0002){ref-type="ref"} The rates of non‐fatal myocardial infarction (MI) were numerically lower with both empagliflozin and canagliflozin vs placebo; the point estimates for non‐fatal stroke numerically favoured placebo vs empagliflozin in the EMPA‐REG OUTCOME trial, and canagliflozin vs placebo in the CANVAS Program, although none of these differences was statistically significant.[1](#dom13299-bib-0001){ref-type="ref"}, [2](#dom13299-bib-0002){ref-type="ref"}

Recently, the The Comparative Effectiveness of Cardiovascular Outcomes (CVD‐REAL) study, a multinational, observational study of over 300 000 patients, found that initiation of SGLT‐2i was associated with a significant reduction in death and heart failure when compared to other glucose‐lowering drugs (oGLDs).[3](#dom13299-bib-0003){ref-type="ref"} Observational data from Nordic countries (CVD‐REAL Nordic) has shown non‐significant point estimates in favour of SGLT‐2i for MI and stroke, using somewhat different statistical methods, and with dapagliflozin dominating the SGLT‐2i group.[4](#dom13299-bib-0004){ref-type="ref"}, [5](#dom13299-bib-0005){ref-type="ref"} However, the effects of SGLT‐2i on atherothrombotic events in the larger CVD‐REAL cohort, including patients from the USA, with a broader representation of SGLT‐2i compounds, have not been explored previously. Accordingly, in this analysis of global CVD‐REAL data, we sought to determine the association between initiation of SGLT‐2i vs oGLDs and MI and stroke events.

2. METHODS {#dom13299-sec-0002}
==========

The CVD‐REAL study design has been described previously.[3](#dom13299-bib-0003){ref-type="ref"} For this analysis, adult patients with T2D who newly initiated treatment with SGLT‐2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs were identified from medical records, claims and national registers collected from 4 countries (USA, Sweden, Norway and Denmark). Because of small numbers of patients and events in Germany and the United Kingdom, we elected not to include data from these countries in this analysis. A non‐parsimonious propensity score was developed separately within each country to predict the likelihood of receiving a prescription for an SGLT‐2i, and patients were matched 1:1 in the 2 treatment groups. In the main on‐treatment analysis, patients were followed from the index date (initiation of the SGLT‐2i or oGLD) until completion of treatment, occurrence of an outcome event, death or censoring. The endpoints of interest were time to MI and stroke. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for each endpoint were generated using Cox regression models, with inverse variance weighting for each country. In a sensitivity analysis, an intent‐to‐treat (ITT) approach was used, in which patients were followed after discontinuation of index treatment. Analyses of de‐identified data were conducted in accordance with local laws and regulations, and received approvals from the respective Scientific/Ethics/Data Protection Committees.

3. RESULTS {#dom13299-sec-0003}
==========

After propensity‐score matching, 205 160 patients were included in the analysis (102 580 in each group), and baseline characteristics were well balanced between the 2 groups. Among participants, the mean age was 57 years, 43% were female, 14% had documented cardiovascular disease before SGLT‐2i or oGLD initiation. In the SGLT‐2i group, of the total exposure time, 49% of patients received dapagliflozin, 44% canagliflozin and 7% empagliflozin. There was significant geographical variation with regard to the specific SGLT‐2i used, with canagliflozin used predominately (75%) in the USA, and dapagliflozin used predominately (90%) in Europe. In patients initiating treatment with oGLDs, the most commonly used classes were insulin (34%), dipeptidyl peptidase‐4 (DPP‐4) inhibitors (18%), sulfonylureas (17%), glucagon‐like peptide‐1 receptor agonists (14%) and metformin (12%).

For the on‐treatment analysis, the mean follow‐up time was 254 days in the SGLT‐2i group and 232 days in the oGLD group. Over 136 524 and 136 626 person‐years of follow‐up (MI and stroke, respectively), there were 779 MIs and 674 strokes (event rate \[ER\], 0.57/ and 0.49/100 person‐years, respectively). Initiation of treatment with SGLT‐2i vs oGLD was associated with a lower risk of MI and stroke (MI: ER, 0.49/100 person‐years for SGLT‐2i vs 0.66/100 person‐years for oGLD; HR, 0.78; 95% CI, 0.65‐0.95; *P* = .01 \[Figure [1](#dom13299-fig-0001){ref-type="fig"}A\]; Stroke: ER, 0.42/100 person‐years for SGLT‐2i vs 0.58/100 person‐years for oGLD; HR, 0.80; 95%CI, 0.66‐0.97; *P* = .02) \[Figure [1](#dom13299-fig-0001){ref-type="fig"}B\], with no evidence of heterogeneity by country.

![Event rates, unadjusted hazard ratios and 95% CIs for acute myocardial infarction (A) and stroke (B) in the on‐treatment population, and for acute myocardial infarction (C) and stroke (D) in the ITT population. Abbreviations: ER, event rate; oGLD, other glucose‐lowering drug; P‐Y, person‐years; SGLT‐2i, sodium‐glucose transporter‐2 inhibitors](DOM-20-1983-g001){#dom13299-fig-0001}

In the ITT analysis, mean follow‐up time was 339 days in the SGLT‐2i group and 332 days in the oGLD group. Over 188 551 and 188 678 person‐years of follow‐up (MI and stroke, respectively), there were 1077 MIs and 968 strokes (ER, 0.57/ and 0.51/100 person‐years, respectively). Initiation of treatment with SGLT‐2i vs oGLD was associated with a lower risk of MI and stroke (MI: ER, 0.52/100 person‐years for SGLT‐2i vs 0.62/100 person‐years for oGLD; HR, 0.85; 95% CI, 0.72‐1.00; *P* = .05; \[Figure [1](#dom13299-fig-0001){ref-type="fig"}C\]; Stroke: ER, 0.45/100 person‐years for SGLT‐2i vs 0.57/100 person‐years for oGLD; HR, 0.83; 95% CI, 0.71‐0.97; *P* = .02 \[Figure [1](#dom13299-fig-0001){ref-type="fig"}D\]), with no evidence of heterogeneity by country.

4. DISCUSSION {#dom13299-sec-0004}
=============

In summary, in this multinational study involving over 200 000 patients, seen within real‐world clinical practice, with a very large number of ischaemic events, initiation of treatment with SGLT‐2i vs oGLD was associated with modestly lower rates of MI and stroke. Although our patient population differed from the EMPA‐REG OUTCOME trial and the CANVAS Program, with a lower prevalence of cardiovascular disease, and thus lower event rates, our results were directionally and numerically consistent with both studies with respect to MI,[1](#dom13299-bib-0001){ref-type="ref"}, [2](#dom13299-bib-0002){ref-type="ref"} with a difference in width of the confidence intervals that is probably related to the greater absolute number of events in our study. Our data were also directionally and numerically consistent with the CANVAS Program with respect to stroke.[1](#dom13299-bib-0001){ref-type="ref"} Our study offers important incremental information with regard to the association between SGLT‐2i use and atherothrombotic events, including MI and stroke, in a broad population of patients with T2D from routine clinical practice. Although prior observational data from Nordic countries (CVD‐REAL Nordic) examined these relationships, and showed numerically lower, non‐significant point estimates for MI and stroke favouring SGLT‐2i vs oGLDs, as well as vs DPP‐4 inhibitors, those investigations evaluated smaller patient samples and numbers of events, used somewhat different statistical approaches, and dapagliflozin dominated the SGLT‐2i group.[4](#dom13299-bib-0004){ref-type="ref"}, [5](#dom13299-bib-0005){ref-type="ref"} Our study substantially expands these findings in the much larger CVD‐REAL cohort, with a greater number of events, with patients from the USA, and with a broader representation of SGLT‐2i compounds. Collectively, our findings complement the results of the completed cardiovascular outcomes trials of SGLT‐2i, and prior observational analyses, and offer additional reassurance with regard to the cardiovascular effects of SGLT‐2i, specifically as it relates to ischaemic events, especially stroke, for which concerns had been raised previously based on a small numerical excess of stroke events with empagliflozin vs placebo, which was not statistically significant.[2](#dom13299-bib-0002){ref-type="ref"}

The results of our study should be considered in the context of several potential limitations. First, given the observational nature of the analyses, and despite robust statistical techniques, including 1:1 propensity matching, a possibility of residual, unmeasured confounding cannot be definitively excluded. Second, despite a large number of accrued patient‐years of follow up, the average duration of follow‐up was relatively limited, as SGLT‐2i use in real‐world practice is still recent; longer‐term follow‐up will be needed to evaluate whether effects are sustained over time. Finally, given that CVD‐REAL is a large, multinational pharmaco‐epidemiologic comparative effectiveness study, it was not designed to examine the potential mechanisms linking the use of SGLT‐2i and associated cardiovascular benefits. However, it is highly unlikely that glucose lowering per se is behind the lower risk of cardiovascular events. As an example, prior analyses from the EMPA‐REG OUTCOME trial have demonstrated little mediation effect of HbA1c on the cardiovascular benefits of empagliflozin.[6](#dom13299-bib-0006){ref-type="ref"} Potential mechanisms may involve reductions in oxidative stress, improvement in endothelial function, neuro‐hormonal modulation and anti‐inflammatory effects, among others.[7](#dom13299-bib-0007){ref-type="ref"}, [8](#dom13299-bib-0008){ref-type="ref"}, [9](#dom13299-bib-0009){ref-type="ref"}, [10](#dom13299-bib-0010){ref-type="ref"}, [11](#dom13299-bib-0011){ref-type="ref"} A metabolic hypothesis has also been proposed, suggesting that a shift in myocardial metabolism from glucose and free fatty acids to ketones may contribute to the cardiovascular benefits of SGLT‐2i.[12](#dom13299-bib-0012){ref-type="ref"} Importantly, this knowledge gap is being examined by mechanistic investigations across the SGLT‐2i class, with more information forthcoming in the near future.
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